Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of...

Related Keywords

Belgium ,Japan ,Canada ,Australia ,Thailand ,South Africa ,Netherlands ,United Kingdom ,Germany ,United States ,Geneva ,Genè ,Switzerland ,China ,Luxembourg ,Monaco ,Grand Duchy Of Luxembourg ,Canton ,America ,Swiss ,Manica Balasegaram ,Pavel Raifeld ,Entasis Therapeutics ,Drug Administration ,World Health Organization ,University Of Alabama ,Nasdaq ,Public Health Agency Of Canada ,Leo Model Foundation ,Jolla Pharmaceutical Company ,Us National Institute Of Allergy ,African Medical Research Council ,Global Antibiotic Research Development Partnership ,Innoviva Inc ,Wellcome ,Entasis Therapeutics Inc ,European Union ,Global Antibiotic Research ,Development Partnership ,Innoviva Specialty Therapeutics ,Executive Director ,Protocol Chair ,Emeritus Professor ,Lancet Infectious Diseases ,Chief Executive Officer ,Therapeutics Limited ,North America ,Grand Duchy ,South African Medical Research Council ,Leo Model ,Infectious Diseases ,Neglected Diseases ,Public Health Agency ,Wellcome Trust ,Specialty Therapeutics ,Specialty Therapeutic ,Markets ,